Cost-utility analysis comparing ocrelizumab vs rituximab in the treatment of relapsing-remitting multiple sclerosis: The Colombian perspective

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.